Kinase Pathway in Human Schwannoma Independent Extracellular Signal-Regulated − Growth Factor Dependent and − Dissecting and Targeting the Growth Factor

Schwannomas are tumors of the nervous system that occur sporadically and in patients with the cancer predisposition syndrome neurofibromatosis type 2 (NF2). Schwannomas and all NF2-related tumors are caused by loss of the tumor suppressor merlin. Using our human in vitro model for schwannoma, we analyzed extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT signaling pathways, their upstream growth factor receptors, and their role in schwannoma cell proliferation and adhesion to find new systemic therapies for these tumors that, to date, are very difficult to treat. We show here that human primary schwannoma cells show an enhanced basal Raf/mitogen-activated protein/ ERK kinase/ERK1/2 pathway activity compared with healthy Schwann cells. Due to a strong and prolonged activation of platelet-derived growth factor receptor B (PDGFRB), which is highly overexpressed, ERK1/2 and AKT activation was further increased in schwannoma, leading to increased proliferation. Using specific inhibitors, we discovered that ERK1/2 activation involves the integrin/focal adhesion kinase/Src/Ras signaling cascades and PDGFRB-mediated ERK1/2 activation is triggered through the phosphatidylinositol 3-kinase/protein kinase C/Src/c-Raf pathway. Due to the complexity of signals leading to schwannoma cell proliferation, potential new therapeutic agents should target several signaling pathways. The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRBmediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas. We conclude that our schwannoma in vitro model can be used to screen for new therapeutic targets in general and that sorafenib is possible candidate for future clinical trials. [Cancer Res 2008;68(13):5236–45]

[1]  M. Birnbaum,et al.  Neuregulin Signaling through a PI3K/Akt/Bad Pathway in Schwann Cell Survival , 2001, Molecular and Cellular Neuroscience.

[2]  J. Pouysségur,et al.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition , 2007, Oncogene.

[3]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[4]  L. Kluwe,et al.  Isolation and Characterization of Schwann Cells from Neurofibromatosis Type 2 Patients , 1998, Neurobiology of Disease.

[5]  Yasin Omar,et al.  Integrin α2-mediated ERK and Calpain Activation Play a Critical Role in Cell Adhesion and Motility via Focal Adhesion Kinase Signaling , 2006, Journal of Biological Chemistry.

[6]  C. Matthies,et al.  Actin-Rich Protrusions and Nonlocalized GTPase Activation in Merlin-Deficient Schwannomas , 2007, Journal of neuropathology and experimental neurology.

[7]  C. Hanemann,et al.  Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. , 2002, Human molecular genetics.

[8]  R. Mirsky,et al.  Regulation of Rat Schwann Cell Po Expression and DNA Synthesis by Insulin‐like Growth Factors In Vitro , 1996, The European journal of neuroscience.

[9]  R. Assoian,et al.  Integrating the MAP kinase signal into the G1 phase cell cycle machinery. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[10]  Seok-Gu Kang,et al.  Merlin inhibits growth hormone-regulated Raf-ERKs pathways by binding to Grb2 protein. , 2006, Biochemical and biophysical research communications.

[11]  M. Giovannini,et al.  Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. , 2007, Cancer research.

[12]  Philip R. Cohen,et al.  Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. , 1998, Science.

[13]  J. Pouysségur,et al.  Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. , 2002, European journal of biochemistry.

[14]  S. Steinberg.  Distinctive activation mechanisms and functions for protein kinase Cdelta. , 2004, The Biochemical journal.

[15]  Gang Li,et al.  The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. , 2005, Frontiers in bioscience : a journal and virtual library.

[16]  H. Coste,et al.  The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. , 1991, The Journal of biological chemistry.

[17]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[18]  C. Hanemann,et al.  Reduced Apoptosis Rates in Human Schwannomas , 2005, Brain pathology.

[19]  N. Ratner,et al.  Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells , 1998, Oncogene.

[20]  D A Lauffenburger,et al.  Analysis of receptor internalization as a mechanism for modulating signal transduction. , 1998, Journal of theoretical biology.

[21]  K. Mielke,et al.  Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. , 2003, Human molecular genetics.

[22]  Nils Cordes,et al.  Signalling via integrins: implications for cell survival and anticancer strategies. , 2007, Biochimica et biophysica acta.

[23]  C. Hanemann,et al.  Improved culture methods to expand schwann cells with altered growth behaviour from CMT1A patients , 1998, Glia.

[24]  T. Hunter,et al.  Focal Adhesion Kinase Overexpression Enhances Ras-dependent Integrin Signaling to ERK2/Mitogen-activated Protein Kinase through Interactions with and Activation of c-Src* , 1997, The Journal of Biological Chemistry.

[25]  J. Pessin,et al.  SOS Phosphorylation and Disassociation of the Grb2-SOS Complex by the ERK and JNK Signaling Pathways (*) , 1996, The Journal of Biological Chemistry.

[26]  Michael B Yaffe,et al.  Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. , 2003, Molecular cell.

[27]  Chang Shin Park,et al.  Kinetic Analysis of Platelet-derived Growth Factor Receptor/Phosphoinositide 3-Kinase/Akt Signaling in Fibroblasts* , 2003, Journal of Biological Chemistry.

[28]  J. Bos.  All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral , 1998, The EMBO journal.

[29]  M. Maa,et al.  Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397 , 2002, Oncogene.

[30]  C. Hanemann,et al.  Pathological Adhesion of Primary Human Schwannoma Cells is Dependent on Altered Expression of Integrins , 2003, Brain pathology.

[31]  J. Chernoff,et al.  Role of Group A p21-activated Kinases in Activation of Extracellular-regulated Kinase by Growth Factors* , 2005, Journal of Biological Chemistry.

[32]  Marketa Zvelebil,et al.  Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.

[33]  E. Pérez-Nadales,et al.  The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation , 2004, The EMBO journal.

[34]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[35]  C. Hanemann,et al.  Differential gene expression between human schwannoma and control Schwann cells , 2006, Neuropathology and applied neurobiology.

[36]  Reinhart Heinrich,et al.  Mathematical models of protein kinase signal transduction. , 2002, Molecular cell.

[37]  R. Bindels,et al.  Effect of protein kinase C activation and down-regulation on active calcium transport. , 1993, Kidney international.

[38]  National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel. , 1994, Archives of neurology.

[39]  J. Fawcett,et al.  Division of labor of Schwann cell integrins during migration on peripheral nerve extracellular matrix ligands. , 1997, Developmental biology.

[40]  Kun-Liang Guan,et al.  Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.

[41]  A. Bretscher,et al.  ERM proteins and merlin: integrators at the cell cortex , 2002, Nature Reviews Molecular Cell Biology.

[42]  S. Deacon,et al.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. , 2008, Chemistry & biology.

[43]  M. Giovannini,et al.  Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. , 2005, Genes & development.

[44]  Andrius Kazlauskas,et al.  PDGF signaling in cells and mice. , 2004, Cytokine & growth factor reviews.

[45]  D. Gutmann,et al.  Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Hancock,et al.  Ras proteins: different signals from different locations , 2003, Nature Reviews Molecular Cell Biology.

[47]  J. Testa,et al.  A Clue to the Therapy of Neurofibromatosis Type 2: NF2/Merlin Is a PAK1 Inhibitor , 2004, Cancer journal.

[48]  D. Parkinson,et al.  Impaired intercellular adhesion and immature adherens junctions in merlin‐deficient human primary schwannoma cells , 2008, Glia.

[49]  N. Kley,et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. , 1993, Cell.

[50]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[51]  Huiqi Pan,et al.  Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. , 2003, International journal of oncology.